Schrodinger, Inc. Stock: price and insider trades · United States

The second pillar is drug discovery. Schrödinger runs internal and partnered programs, which can generate collaboration revenue, milestone payments and potential longer-term upside from pipeline assets. This segment gives the company exposure to the economics of biotech value creation, but also adds higher volatility and execution risk versus pure software businesses. Recent company updates in 2026 highlighted progress across proprietary preclinical and clinical-stage programs, including SGR-1505, SGR-3515 and other pipeline assets, as well as continued strategic collaboration activity.

Competitively, Schrödinger occupies a strong niche at the intersection of computational chemistry, AI and drug discovery. Its long operating history and scientific reputation matter: unlike newer AI-first entrants, Schrödinger combines machine learning with established physics-based simulation, which it presents as a core differentiator. That positioning gives the company credibility with large pharmaceutical customers seeking higher-quality hit finding, lead optimization and better R&D productivity.

Geographically, Schrödinger serves a global client base and maintains an international presence across North America, Europe and Asia. In its latest 2026 announcements, the company reported continued growth in annual contract value, emphasized its transition to hosted software licensing, and announced plans for Bunsen, an agentic AI co-scientist. It also pointed to customer traction and collaboration momentum, including externally validated partnerships. For investors in France, Belgium and Switzerland, Schrödinger should be viewed as a science-driven technology company listed on Nasdaq in the United States, with a business model that blends recurring software revenue, strategic pharma partnerships and pipeline optionality.